Ticker >

Piramal Pharma share price

Piramal Pharma Ltd.

NSE: PPLPHARMA BSE: 543635 SECTOR: Pharmaceuticals & Drugs  69k   107   36

140.00
+1.25 (0.90%)
NSE: Today, 03:59 PM

Price Summary

Today's High

₹ 143.25

Today's Low

₹ 133.7

52 Week High

₹ 149

52 Week Low

₹ 67.92

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

18521.27 Cr.

Enterprise Value

20084.39 Cr.

No. of Shares

132.29 Cr.

P/E

115.87

P/B

2.89

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  48.52

CASH

64.16 Cr.

DEBT

1627.28 Cr.

Promoter Holding

35.02 %

EPS (TTM)

₹  1.21

Sales Growth

3.08%

ROE

1.34 %

ROCE

3.64%

Profit Growth

-81.09 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year3.08%
3 YearNA
5 YearNA

Profit Growth

1 Year-81.09%
3 YearNA
5 YearNA

ROE%

1 Year1.34%
3 Year7.75%

ROCE %

1 Year3.64%
3 Year9.9%

Debt/Equity

0.3093

Price to Cash Flow

258.97

Interest Cover Ratio

2.06748942780703

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 35.02 0
Sep 2023 35.02 0
Jun 2023 34.79 0
Mar 2023 34.79 0
Dec 2022 34.79 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 20.7719076150771 days.

 Limitations

  • The company has shown a poor profit growth of 0% for the Past 3 years.
  • The company has shown a poor revenue growth of 0% for the Past 3 years.
  • Company has a poor ROE of 7.74841969249947% over the past 3 years.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high PE of 115.87.
  • The company is trading at a high EV/EBITDA of 35.6399.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 813.29 1054.58 846.43 994.24 1024.14
Total Expenditure 786.02 965.03 829.84 908.08 898.61
Operating Profit 27.27 89.55 16.59 86.16 125.53
Other Income 53.88 62.88 26.68 89.08 33.11
Interest 33.22 33.78 33.8 28.22 17.42
Depreciation 47.19 53.01 50.37 50.83 51.56
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.74 65.64 -40.9 96.19 89.66
Tax 3.16 23.94 -7.54 19.03 15.32
Profit After Tax -2.42 41.7 -33.36 77.16 74.34
Adjusted EPS (Rs) -0.02 0.34 -0.27 0.58 0.56

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023
Net Sales 2938.81 3340.42 3443.22
Total Expenditure 2319.88 2865.14 3345.69
Operating Profit 618.93 475.28 97.53
Other Income 197.97 224.79 341.07
Interest 4.71 57.29 115.87
Depreciation 143.64 165.37 192.08
Exceptional Items 18.23 -15.08 -6.96
Profit Before Tax 686.78 462.33 123.69
Tax 115.28 94.79 54.19
Net Profit 571.5 367.54 69.5
Adjusted EPS (Rs.) 5.61 3.03 0.57

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 994.6 1185.91 1193.32
Total Reserves 3106.02 3937.21 4068.47
Borrowings 0 477.12 592.34
Other N/C liabilities 184.38 323.6 490.83
Current liabilities 1566.96 1655.39 1951.29
Total Liabilities 5851.96 7579.23 8296.25
Assets
Net Block 1626.81 2438.98 2601.87
Capital WIP 79.34 157.47 136.5
Intangible WIP 41.66 247.69 280.07
Investments 1591.52 1592.52 1646.87
Loans & Advances 649.84 963.54 1282.22
Other N/C Assets 0 0.04 0.04
Current Assets 1862.79 2178.99 2348.68
Total Assets 5851.96 7579.23 8296.25
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023
Profit from operations 668.55 477.41 130.65
Adjustment -310.48 42.92 50.7
Changes in Assets & Liabilities -228.06 -168.48 -49.8
Tax Paid -95.29 -102.66 -60.03
Operating Cash Flow 34.72 249.19 71.52
Investing Cash Flow -4382.89 -1164.62 -435.05
Financing Cash Flow 4494.16 896.4 290.12
Net Cash Flow 145.99 -19.03 -73.41

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 34.79 34.79 34.79 35.02 35.02
aasan corporate solutions... 0.68 0.68 0.68 0.68 0.68
anand piramal trust 0.05 0.05 0.05 0.05 0.05
master dev piramal deyoun... 0.02 0.02 0.02 0.01 0.01
mr. ajay g. piramal 0.04 0.04 0.04 0.04 0.04
mr. anand piramal 0.07 0.07 0.07 0.07 0.07
mr. peter deyoung 0.04 0.04 0.04 0.03 0.03
ms. anya piramal deyoung 0.02 0.02 0.02 0.01 0.01
ms. nandini piramal 0.02 0.02 0.02 0.02 0.02
nandini piramal trust 0.04 0.04 0.04 0.04 0.04
piramal welfare trust (fo... 0.80 0.80 0.80 0.80 0.80
prl realtors llp 3.01 3.01 3.01 3.01 3.01
the ajay g. piramal found... 0.33 0.33 0.33 0.33 0.33
the sri krishna trust thr... 26.44 26.44 26.44 26.67 26.67
v3 designs llp 3.25 3.25 3.25 3.25 3.25
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 65.21 65.21 65.21 64.98 64.98
ca alchemy investments 20.00 20.00 20.00 18.04 18.04
college retirement equiti... 1.08 1.27 1.59 1.58 1.20
east bridge capital maste... 2.17 2.17 2.17 2.17 4.71
hdfc mutual fund - hdfc f... - - - - 1.80
icici prudential value di... - - - 2.16 1.31
indiahold limited 1.45 1.45 1.45 1.31 1.31
investor education and pr... - - - - 0.24
life insurance corporatio... 3.88 3.88 3.88 3.49 2.05
llp 0.81 - - 0.98 0.99
east bridge capital maste... 3.46 3.41 3.21 2.74 -
investor education and pr... 0.27 0.27 0.27 0.24 -
11998374 - - 1.01 - -
caisse de depot et placem... 5.65 5.53 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Piramal Pharma’s consumer products division forays into men's grooming segment11 Apr 2024, 4:31PM Piramal Pharma informs about disclosure 18 Mar 2024, 3:18PM USFDA conducts PAI inspection at Piramal Pharma’s USA facility 24 Feb 2024, 3:09PM Piramal Pharma informs about disclosure24 Feb 2024, 2:29PM Piramal Pharma submits analyst meet intimation21 Feb 2024, 4:58PM USFDA conducts PAI inspection at Piramal Pharma’s USA facility7 Feb 2024, 6:20PM Piramal Pharma - Quaterly Results30 Jan 2024, 8:48PM Piramal Pharma - Quaterly Results30 Jan 2024, 8:48PM Piramal Pharma’s division launches new concentration of Zinc Sulfate for Injection in U.S.17 Jan 2024, 9:21AM Piramal Pharma gets EIR for manufacturing facility in USA9 Nov 2023, 12:58PM Piramal Pharma - Quaterly Results27 Oct 2023, 10:15PM Piramal Pharma - Quaterly Results27 Oct 2023, 10:15PM Piramal Pharma informs about conference call with investor18 Oct 2023, 5:11PM Piramal Pharma’s PPS business launches high-throughput screening facility16 Oct 2023, 6:35PM USFDA conducts GMP Inspection at Piramal Pharma’s Bethlehem facility29 Sep 2023, 12:16PM Piramal Pharma informs about disclosure 12 Sep 2023, 5:17PM Piramal Pharma informs about sustainability report 8 Sep 2023, 2:21PM Piramal Pharma informs about newspaper advertisement24 Aug 2023, 5:04PM Piramal Pharma - Quaterly Results3 Aug 2023, 9:06PM Piramal Pharma - Quaterly Results3 Aug 2023, 9:06PM Piramal Pharma gets Sebi's nod to raise up to Rs 1,050 crore through rights issue of shares18 Jul 2023, 4:00PM Piramal Pharma informs about press release 6 Jun 2023, 5:01PM Piramal Pharma informs about disclosure1 Jun 2023, 9:59AM Piramal Pharma reports 75% fall in Q4 consolidated net profit25 May 2023, 11:44AM Piramal Pharma - Quaterly Results24 May 2023, 9:49PM Piramal Pharma - Quaterly Results24 May 2023, 9:49PM Piramal Pharma informs about analyst meet23 May 2023, 5:06PM Piramal Pharma informs about board meeting 18 May 2023, 10:59AM Piramal Pharma informs about conference call18 May 2023, 10:52AM Piramal Pharma informs about disclosure1 Apr 2023, 12:25PM Piramal Pharma informs about newspaper publication18 Feb 2023, 1:59PM Piramal Pharma informs about notice of postal ballot 18 Feb 2023, 11:00AM USFDA issues EIR to Piramal Pharma’s USA facility16 Feb 2023, 3:14PM Piramal Pharma reports consolidated net loss of Rs 90.18 crore in Q3FY239 Feb 2023, 12:47PM Piramal Pharma - Quaterly Results8 Feb 2023, 9:08PM Piramal Pharma - Quaterly Results8 Feb 2023, 9:08PM Piramal Pharma gets two observations from USFDA for Sellersville facility16 Jan 2023, 10:22AM USFDA conducts PAI and GMP inspection at Piramal Pharma’s Lexington facility11 Jan 2023, 2:21PM Piramal Pharma informs about investors meet3 Jan 2023, 3:12PM Piramal Pharma reports consolidated net loss of Rs 37.34 crore in Q2FY239 Nov 2022, 10:20AM Piramal Pharma - Quaterly Results8 Nov 2022, 9:31PM Piramal Pharma - Quaterly Results8 Nov 2022, 9:31PM

Piramal Pharma Stock Price Analysis and Quick Research Report. Is Piramal Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Piramal Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Piramal Pharma cash from the operating activity was Rs 71.52 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Piramal Pharma has a Debt to Equity ratio of 0.3093 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Piramal Pharma , the EPS growth was -81.2078763050086 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Piramal Pharma has OPM of 2.832523045289 % which is a bad sign for profitability.
     
  • ROE: Piramal Pharma have a poor ROE of 1.33848054532971 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Piramal Pharma is Rs 140.1. One can use valuation calculators of ticker to know if Piramal Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Piramal Pharma
X